Paul Feuerstadt, MD, FACG, AGAF, FRCPE

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Ferring Pharmaceuticals
    Topic:
    C. difficile infection
    Date added:
    01/15/2026
    Date updated:
    01/15/2026
  • Attribution:
    Self
    Type of financial relationship:
    Speaker
    Ineligible company:
    Ferring Pharmaceuticals
    Topic:
    C. difficile infection
    Date added:
    01/15/2026
    Date updated:
    01/15/2026
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Nestle Health Sciences
    Topic:
    C. difficile infection
    Date added:
    01/15/2026
    Date updated:
    01/15/2026
  • Attribution:
    Self
    Type of financial relationship:
    Speaker
    Ineligible company:
    Nestle Health Sciences
    Topic:
    C. difficile infection
    Date added:
    01/15/2026
    Date updated:
    01/15/2026
  • Attribution:
    Self
    Type of financial relationship:
    Advisor
    Ineligible company:
    Astrazenica
    Topic:
    C. difficile infection
    Date added:
    01/15/2026
    Date updated:
    01/15/2026
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Sanofi/Regeneron
    Topic:
    Eosinophilic Esophagitis
    Date added:
    01/15/2026
    Date updated:
    01/15/2026
  • Attribution:
    Self
    Type of financial relationship:
    Speaker
    Ineligible company:
    Sanofi/Regeneron
    Topic:
    Eosinophilic Esophagitis
    Date added:
    01/15/2026
    Date updated:
    01/15/2026
Return to 3rd Great GI Debates